Gene variant and capecitabine side effects in colorectal and breast cancer
Studies how a CES1 gene variant affects capecitabine side effects in cancer patients.
Plain-language title generated from the registry record
Registry title: Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
Key facts
- Where
- Shibīn al Kawm, EgyptSee the site
Where in Egypt
- Department of Clinical Oncology, Faculty of Medicine, Menoufia UniversityShibīn al Kawm, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT06765252
- Record updated
- 9 January 2025
- Original description
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.Read full original descriptionShow less
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.
Inclusion: Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy; Age > 18 years; ECOG PS 0-2.
Exclusion: Patients treated with irinotecan; Patients having inability to take oral medication; Patients with malabsorption syndrome; Patients with chronic diarrhea as ulcerative colitis or Crohn's disease; Lack of physical integrity of the upper gastrointestinal tract; Patients with poor performance status.